🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jing Li

University of South Carolina

ORCID: 0000-0003-2065-9040
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma”.

Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma

Neuro-Oncology(2025)10.1093/neuonc/noaf257
N/A
0.241DataRank · unranked
4 citations

An‐Chi Tien, Jun Jiang, James McNamara, Yu‐Wei Chang, Chelsea Montgomery +17 more

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.1c01951
N/A
0DataRank · unranked
38 citations

Chen Cheng, Jing Li, Lili Wang, Alexander A. Chumanevich, Donald C. Porter +6 more

CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins

Nucleic Acids Research(2023)10.1093/nar/gkad538
N/A
0DataRank · unranked
68 citations

Jing Li, Li Zhang, Lili Wang, Chen Cheng, Hao Ji +20 more

Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.2021
N/A
0DataRank · unranked
37 citations

Jun Jiang, Jianmei Wu, Xun Bao, Nader Sanai, Jing Li

Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2414501121
N/A
0DataRank · unranked
7 citations

Jiaxin Liang, Amanda C. Sharko, Thomas A. Hilimire, Jing Li, Jürgen Loskutov +9 more

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

Journal of Clinical Investigation(2024)10.1172/jci176709
N/A
0DataRank · unranked
22 citations

Thomas A. Hilimire, Yueying Liu, Lili Wang, Jiaxin Liang, Balázs Győrffy +21 more

CDK19 and CDK8 Mediator kinases drive androgen-independent in vivo growth of castration-resistant prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.08.552491
N/A
0DataRank · unranked
2 citations

Thomas A. Hilimire, Yueying Liu, Lili Wang, Jiaxin Liang, Balázs Győrffy +19 more